T he current standard of care fails to treat the vast majority of patients with glioblastoma (GBM) 1 leaving them with a median survival period of 12.2 to 18.2 mo. 2 Classifying the cellular basis that harbors mutations driving GBM evolution can provide a fundamental basis for halting disease recurrence through the development of novel therapeutics. Previous work has suggested that GBM arises from the accrual of somatic mutations in neural stem cells, which harbor preserved proliferative ability, within the subventricular zone (SVZ). 3 An innovative investigation by Lee et al 4 published in Nature provides molecular genetic confirmation showing astrocyte-like neural stem cells in the SVZ to be the cell of origin that encompasses the driver mutations of human GBM. The team performed deep sequencing of tissue acquired during tumor resection surgery for 28 patients with isocitrate dehydrogenase (IDH) wild-type GBM, which included sampling of normal cortex, tumor and normal SVZ tissue. They found that 56.3% of patients contained low-level GBM driver mutations in the SVZ that were similarly observed at high levels in the associated tumors, with a substantial portion involving cancerassociated mutations including EGFR, PTEN, and p53 (Figure) . Furthermore, 42.3% of cases involved somatic mutations in the TERT promoter of the SVZ that were shared with the associated tumors.
Lee et al 4 developed a murine model of EGFR, PTEN, and p53 genes confined to the neural stem cells within the SVZ using in vivo electroporation of a Cre-containing CRISPR-Cas9 vector. The team showed, by immunostaining, that neural stem cells harboring driver mutations originate from the SVZ with subsequent migration and seeding of GBM to distant brain sites. These findings strongly suggest that the cell of origin of GBM resides in the SVZ, though there remains the likelihood that GBM cells could also travel toward the SVZ.
Notably, the discoveries also emphasize that acquirement of the TERT promoter mutation permits the protracted selfrenewal ability of NSCs, allowing the development of somatic mutation induced glioma-genesis. This investigation's findings may be valuable to the advancement of new therapeutic approaches for GBM by targeting neural stem cells harboring driver mutations. Further preclinical corroboration of these exciting findings is necessary prior to translation and adaptation into the clinical arena.
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